08.00-09.30   HALL 2


Late Breaking Clinical Trials 1
Chairs: Giuseppe Remuzzi, Bergamo, Italy
            Mehmet Sukru Sever, Istanbul, Turkey


CCL2 inhibition with emapticap pegol (NOX‐E36) in type 2 diabetic patients with albuminuria

Hermann Haller, Germany

Red blood cell transfusion and the risk of heart failure in patients with advanced chronic kidney disease

Brian Bradbury, Thousand Oaks, USA

Efficacy and safety of canagliflozin (CANA) in patients with type 2 diabetes mellitus who had estimated glomerular filtration rate reduction during treatment

Ronan Roussel, France

C-reactive protein out-performs cystatin c for assessing risk for near-term deaths among participants in the REGARDS study

David G. Warnock, Birmingham, USA

Dental health and risk of all-cause and cardiovascular mortality in adults with end-stage kidney disease: a multinational cohort study

Giovanni Strippoli, Bari, Italy


back to the timetable